Join the Rivaroxaban group to help and get support from people like you.
Rivaroxaban News
Bleeding Higher With Standard-Dose DOACs in Nonvalvular A-Fib
THURSDAY, Nov. 16, 2023 – For nursing home residents with nonvalvular atrial fibrillation, the rate of bleeding is higher with standard- versus reduced-dose direct acting oral anticoagulants...
DOACs Reduce Dementia Risk Versus Warfarin in A-Fib
THURSDAY, Sept. 7, 2023 – For patients with atrial fibrillation (AF), the use of direct-acting oral anticoagulants (DOACs) significantly reduces dementia risk compared with warfarin, according to a...
FDA Approves Two New Indications for Xarelto (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for X...
FDA Approves Xarelto (rivaroxaban) to Help Prevent Blood Clots in Acutely Ill Medical Patients
RARITAN, N.J., October 14, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) for the ...
FDA Approves Xarelto to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
TITUSVILLE, NJ, October 11, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban) to r...
FDA Approves Portola Pharmaceuticals’ Andexxa, First and Only Antidote for the Reversal of Factor Xa Inhibitors
SOUTH SAN FRANCISCO, Calif., May 03, 2018 (GLOBE NEWSWIRE) – Portola Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Andexxa [coagulation factor...
FDA Approves New 10 mg Dosing for Xarelto (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
TITUSVILLE, NJ, OCTOBER 30, 2017 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the 10 mg once-daily dose of Xarelto (rivaroxaban) for reducing t...
FDA Expands Use of Xarelto to Treat, Reduce Recurrence of Blood Clots
November 2, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to...
FDA Approves Xarelto to Prevent Stroke in People With Common Type of Abnormal Heart Rhythm
SILVER SPRING, Md., Nov. 4, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Atrial Fibrillation, Cardiovascular Risk Reduction, Coronary Artery Disease (CAD), Deep Vein Thrombosis (DVT), Deep Vein Thrombosis, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis - Prophylaxis, Deep Vein Thrombosis - Recurrent Event, Prevention of Thromboembolism in Atrial Fibrillation, Pulmonary Embolism, Pulmonary Embolism - Recurrent Event